Related Experiment Video
Updated: Jun 25, 2026

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders
Petra E Spies1, René J F Melis, Magnus J C Sjögren
1Department of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Donders Centre for Neuroscience, Nijmegen, The Netherlands. p.spies@ger.umcn.nl
Cerebrospinal fluid (CSF) alpha-synuclein levels did not differ between dementia with Lewy bodies (DLB) patients and those with Alzheimer's disease, vascular dementia, or frontotemporal dementia. Therefore, CSF alpha-synuclein is not a reliable biomarker for distinguishing DLB from other dementia types.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Neurodegenerative Diseases
Background:
- Alpha-synuclein is a key component of Lewy bodies in dementia with Lewy bodies (DLB).
- Intraneuronal accumulation of alpha-synuclein in DLB suggests potential diagnostic value as a biomarker.
- Hypothesis: Lower CSF alpha-synuclein levels in DLB compared to other dementias.
Purpose of the Study:
- To investigate CSF alpha-synuclein levels across various dementia disorders.
- To evaluate the diagnostic utility of CSF alpha-synuclein in differentiating DLB from other dementia types.
Main Methods:
- Analysis of CSF alpha-synuclein levels.
- Study cohort included 40 DLB patients, 131 Alzheimer's disease patients, 28 vascular dementia patients, and 39 frontotemporal dementia patients.
Main Results:
- No significant differences were observed in CSF alpha-synuclein levels between DLB patients and patients with Alzheimer's disease, vascular dementia, or frontotemporal dementia.
- CSF alpha-synuclein did not show diagnostic value in discriminating between DLB and other dementia types in this cohort.
Conclusions:
- In clinically diagnosed patients, CSF alpha-synuclein is not a useful biomarker for differentiating DLB from other common dementia disorders.
- Further research may be needed to explore other potential biomarkers for DLB diagnosis.
Related Concept Videos
Dementia l: Introduction
Neural Regulation
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Parkinson Disease ll: Pathophysiology

